Policy & Regulation
GSK reports positive phase III data for bepirovirsen in chronic hepatitis B
28 May 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) on Thursday reported positive phase III results for bepirovirsen, its investigational treatment for chronic hepatitis B, with poole...
Sanofi's venglustat receives FDA priority review for type 3 Gaucher disease
28 May 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that the US Food and Drug Administration (FDA) has granted priority review for its new drug ...
Antengene receives Chinese clearance for Phase III study of ATG-022 in CLDN18.2+ advanced gastric/GEJ cancer
28 May 2026 - Chinese biotech company Antengene Corporation Limited (SEHK:6996) announced on Wednesday that, following review by the Center for Drug Evaluation (CDE) of China's National Medical P...
Ribo submits Phase 2 trial application for RBD1119 to European regulator
28 May 2026 - China-based Suzhou Ribo Life Science Co Ltd (HK:06938) and Sweden-based Ribocure Pharmaceuticals AB (together 'Ribo') announced on Wednesday the submission of a Phase 2 clinica...
US FDA extends review timeline for AstraZeneca's camizestrant application
27 May 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) announced on Wednesday that the US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee...
Circio and AaviGen partner to develop next-generation gene therapies for heart disease
27 May 2026 - Biotechnology companies Circio Holding ASA (OSE:CRNA) and AaviGen GmbH on Wednesday announced a research collaboration to develop circVec-enhanced AAV vectors engineered for targeted, lo...